A proteome-wide atlas of drug mechanism of action
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, because most FDA-approved drugs target proteins and protein and RNA levels often correlate weakly, protein-level changes are likely to provide the more relevant readout of compound action (8, 9, 10, 11).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG as a reference resource for gene and protein annotation
Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1070 · Cited by 7,387
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationCorrelation between Protein and mRNA Abundance in Yeast
Gygi, S. P., Rochon, Y., Franza, B. R., & Aebersold, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1720 · Cited by 3,819
Self-citationA Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
On the Dependency of Cellular Protein Levels on mRNA Abundance
Liu, Y., Beyer, A., & Aebersold, R. (2016) · Cell · doi:10.1016/j.cell.2016.03.014 · Cited by 3,221
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citation
Research works printed but not linked: 51
- Litichevskiy, L. et al. A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations. Cell Syst. 6, 424–443e7 (2018). · DOI · Paper page
- Abelin, J. G. et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol. Cell Proteomics 15, 1622–1641 (2016). · DOI · Paper page
- Chernobrovkin, A. et al. Functional identification of target by expression proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci. Rep. 5, 11176 (2015). · DOI
- Saei, A. A. et al. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nat. Commun. 10, 5715 (2019). · DOI · Paper page
- Ruprecht, B. et al. A mass spectrometry-based proteome map of drug action in lung cancer cell lines. Nat. Chem. Biol. 16, 1111–1119 (2020). · DOI
- Bian, Y. et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. Nat. Commun. 11, 157 (2020). · DOI · Paper page
- Li, J. et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat. Methods 17, 399–404 (2020). · DOI · Paper page
- Thompson, A. et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895–1904 (2003). · DOI · Paper page
- Li, J. et al. Proteome-wide mapping of short-lived proteins in human cells. Mol. Cell 81, 4722–4735 e5 (2021). · DOI · Paper page
- Schweppe, D. K. et al. Full-featured, real-time database searching platform enables fast and accurate multiplexed quantitative proteomics. J. Proteome Res. 19, 2026–2034 (2020). · DOI · Paper page
- Erickson, B. K. et al. Active instrument engagement combined with a real-time database search for improved performance of sample multiplexing workflows. J. Proteome Res. 18, 1299–1306 (2019). · DOI · Paper page
- Misra, S., Ghatak, S. & Toole, B. P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 280, 20310–20315 (2005). · DOI · Paper page
- Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477–2488 (2014). · DOI · Paper page
- Foulds, C. E. Disrupting a negative feedback loop drives endocrine therapy-resistant breast cancer. Proc. Natl Acad. Sci. USA 115, 8236–8238 (2018). · DOI
- Iskar, M. et al. Drug-induced regulation of target expression. PLoS Comput. Biol. 6, e1000925 (2010). · DOI · Paper page
- Liu, S. et al. Structure-guided design and development of potent and selective dual bromodomain 4 (BRD4)/polo-like kinase 1 (PLK1) inhibitors. J. Med. Chem. 61, 7785–7795 (2018). · DOI
- Wrobel, A. et al. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors. J. Antibiot. (Tokyo) 73, 5–27 (2020). · DOI · Paper page
- Zhang, Y. et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat. Cell Biol. 13, 623–629 (2011). · DOI · Paper page
- Wang, W. et al. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13, 524–532 (2015). · DOI · Paper page
- Thorsell, A. G. et al. Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J. Med. Chem. 60, 1262–1271 (2017). · DOI · Paper page
- Strimmer, K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 24, 1461–1462 (2008). · DOI · Paper page
- Villalonga-Planells, R. et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6, e18588 (2011). · DOI · Paper page
- Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 Inhibitors and the potential for differential clinical activity. Cell Chem. Biol. 26, 1067–1080 e8 (2019). · DOI · Paper page
- Picaud, S. et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl Acad. Sci. USA 110, 19754–19759 (2013). · DOI · Paper page
- Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011). · DOI · Paper page
- Boada-Romero, E. et al. TMEM59 defines a novel ATG16L1-binding motif that promotes local activation of LC3. EMBO J. 32, 566–582 (2013). · DOI
- Gremke, N. et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat. Commun. 11, 4684 (2020). · DOI · Paper page
- Mauvezin, C. & Neufeld, T. P. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy 11, 1437–1438 (2015). · DOI · Paper page
- Shen, S. et al. Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. Oncogene 30, 4544–4556 (2011). · DOI
- Becker, E. & Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 134, 510–521 (1999). · DOI
- Cukierman, D. S. et al. Aroylhydrazones constitute a promising class of ‘metal-protein attenuating compounds’ for the treatment of Alzheimer’s disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone. J. Biol. Inorg. Chem. 23, 1227–1241 (2018). · DOI
- Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019). · DOI · Paper page
- Li, F. et al. Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1alpha and induces DNA damage by sequestering ferrous iron. Cell Death Dis. 9, 1025 (2018). · DOI
- Deeks, E. D. Ibrutinib: a review in chronic lymphocytic leukaemia. Drugs 77, 225–236 (2017). · DOI
- Lou, Y. et al. Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J. Med. Chem. 58, 512–516 (2015). · DOI · Paper page
- Li, J. et al. Selection of heating temperatures improves the sensitivity of the proteome integral solubility alteration assay. J. Proteome Res. 19, 2159–2166 (2020). · DOI · Paper page
- An, H. et al. TEX264 is an endoplasmic reticulum-resident ATG8-Interacting protein critical for ER remodeling during nutrient stress. Mol. Cell 74, 891–908e10 (2019). · DOI · Paper page
- Chino, H. et al. Intrinsically disordered protein TEX264 mediates ER-phagy. Mol. Cell 74, 909–921e6 (2019). · DOI · Paper page
- Tricklebank, M. D. JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain. Br. J. Pharmacol. 150, 381–382 (2007). · doi:10.1038/sj.bjp.0707007
- Baumli, S. et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 27, 1907–1918 (2008). · DOI · Paper page
- Chang, H. W. et al. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. Sci. Adv. 4, eaav2131 (2018). · DOI
- Schenone, M. et al. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232–240 (2013). · DOI · Paper page
- Huttlin, E. L. et al. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 184, 3022–3040 e28 (2021). · doi:10.1016/j.cell.2021.04.011 · Paper page
- Hughes, C. S. et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol. 10, 757 (2014). · DOI · Paper page
- Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68–85 (2019). · DOI · Paper page
- Liu, X., Gygi, S. P. & Paulo, J. A. A semiautomated paramagnetic bead-based platform for isobaric tag sample preparation. J. Am. Soc. Mass. Spectrom. 32, 1519–1529 (2021). · DOI
- Navarrete-Perea, J., Yu, Q., Gygi, S. P. & Paulo, J. A. Streamlined tandem mass tag (SL-TMT) protocol: an efficient strategy for quantitative (phospho)proteome profiling using tandem mass tag-synchronous precursor selection-MS3. J. Proteome Res. 17, 2226–2236 (2018). · DOI · Paper page
- Rad, R. et al. Improved monoisotopic mass estimation for deeper proteome coverage. J. Proteome Res. 20, 591–598 (2021). · DOI · Paper page
- Savitski, M. M., Wilhelm, M., Hahne, H., Kuster, B. & Bantscheff, M. A scalable approach for protein false discovery rate estimation in large proteomic data sets. Mol. Cell Proteomics 14, 2394–2404 (2015). · DOI · Paper page
- Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003). · DOI · Paper page
- Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016). · DOI · Paper page
Cited by
Empowering biomedical discovery with AI agents
Gao, S., Fang, A., Huang, Y., Giunchiglia, V., Noori, A., Schwarz, J. R., Ektefaie, Y., Kondic, J., & Zitnik, M. (2024) · Cell · doi:10.1016/j.cell.2024.09.022 · Cited by 315
Degradome analysis to identify direct protein substrates of small-molecule degraders
Jochem, M., Schrempf, A., Wagner, L.-M., Segal, D., Cisneros, J., Ng, A., Winter, G. E., & Krijgsveld, J. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.007 · Cited by 25
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Metadata
- Authors
- Mitchell, D. C., Kuljanin, M., Li, J., Van Vranken, J. G., Bulloch, N., Schweppe, D. K., Huttlin, E. L., & Gygi, S. P.
- Venue
- Nature Biotechnology
- Published
- 2023-01-02
- Volume
- 41
- Issue
- 6
- Pages
- 845-857
- ISSN
- 1087-0156
- 1546-1696
- Cited by
- 164
- References
- 26
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A proteome-wide atlas of drug mechanism of action. https://app.cochat.ai/papers/10.1038/s41587-022-01539-0
- The paper
- Mitchell, D. C., Kuljanin, M., Li, J., Van Vranken, J. G., Bulloch, N., Schweppe, D. K., Huttlin, E. L., & Gygi, S. P. (2023). A proteome-wide atlas of drug mechanism of action. Nature Biotechnology. https://doi.org/10.1038/s41587-022-01539-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.